Concepedia

Author

Barbara Grant

University of Vermont

Also Known As

B W Grant, B. W. Grant, BARBARA W. GRANT, Barbara Grant, Barbara W. Grant

38

Publications

5.9K

Citations

19

H-Index

42

Concepts

All Affiliations

University of VermontCornell UniversityPharmacyclics (United States)The Ohio State UniversityThe University of Texas MD Anderson Cancer Center
BG

About

Barbara Grant is an author at University of Vermont specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

859

2

Health Sciences

3

3

523

3

Allergy

2

2

193

4

Engineering

1

1

30

5

Biomolecular Engineering

1

1

30

Barbara Grant

×

24

Publications

5.9K

Citations

19

H-Index

YearCitations

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Richard R. Furman, Steven Coutré,

New England Journal of Medicine

2013

2.2K

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman,

Journal of Clinical Oncology

2012

1.1K

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson,

Journal of Clinical Oncology

2013

489

Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

Patrick G. Morris, Denise D. Correa, Joachim Yahalom,

Journal of Clinical Oncology

2013

476

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Susan O’Brien, Richard R. Furman, Steven Coutré,

The Lancet Oncology

2013

463

Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma

Gaurav Shah, Joachim Yahalom, Denise D. Correa,

Journal of Clinical Oncology

2007

397

Immune cell populations in cutaneous delayed-type hypersensitivity.

Jeffrey L. Platt, Barbara Grant, Allison A. Eddy,

The Journal of Experimental Medicine

1983

182

Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.

James A. Stewart, Jerome L. Belinson, Ann L. Moore,

PubMed

1990

60

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

John C. Byrd, Richard R. Furman, Steven Coutré,

Blood

2012

56

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

Susan O’Brien, Jan A. Burger, Kristie A. Blum,

Blood

2011

56

Page 1